[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-363023-105":59,"doc-detail-363023-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","hif-1-sirna-enhances-the-efficacy-of-erlotinib-in-non-small-cell-lung-cancer-a-novel-strategy-to-reverse-hypoxia-induced-drug-resistance","HIF-1α siRNA Enhances the Efficacy of Erlotinib in Non-small Cell Lung Cancer - A Novel Strategy to Reverse Hypoxia-Induced Drug Resistance","","Non-small cell lung cancer (NSCLC) continues to cause high cancer-related mortality, and acquired resistance limits EGFR tyrosine kinase inhibitor benefit. This study examines how HIF-1α contributes to drug resistance and tests a combined approach to counter EGFR-TKI resistance driven by tumor hypoxia and HIF-1α stabilization. HIF-1α knockdown and erlotinib treatment reduce proliferation, induce apoptosis, and suppress invasion synergistically.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/hif-1-sirna-enhances-the-efficacy-of-erlotinib-in-non-small-cell-lung-cancer-a-novel-strategy-to-reverse-hypoxia-induced-drug-resistance/363023/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/hif-1-sirna-enhances-the-efficacy-of-erlotinib-in-non-small-cell-lung-cancer-a-novel-strategy-to-reverse-hypoxia-induced-drug-resistance/363023.png","ImageObject",300,407,{"name":92,"@type":93},"Putri","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",15,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why does hypoxia and HIF-1α matter in EGFR-TKI resistance in NSCLC?","Question",{"text":113,"@type":114},"HIF-1α stabilization promotes adaptation to the hypoxic microenvironment and supports metabolic and signaling changes that drive resistance. This leads to impaired long-term efficacy of EGFR-TKIs.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How was HIF-1α investigated in the study’s experiments?",{"text":118,"@type":114},"HIF-1α expression and downstream targets were measured in H1975 and A549 cells using RT-qPCR and Western blot. Functional assays assessed proliferation, apoptosis, invasion, lactate production, and ROS after HIF-1α siRNA and/or erlotinib treatment.",{"name":120,"@type":111,"acceptedAnswer":121},"What is the main finding from combining HIF-1α siRNA with erlotinib?",{"text":122,"@type":114},"The combination synergistically suppresses cell proliferation, induces apoptosis, and inhibits invasion more effectively than single-agent treatment. The study links this effect to disruption of metabolic reprogramming and hypoxia adaptation.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},363023,1790193632,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":105,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962085571259,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Drugs in R&D (2026) 26:101–115  \n[https://doi.org/10.1007/s40268-025-00534-5](https://doi.org/10.1007/s40268-025-00534-5)  \nHIF‑1α siRNA Enhances the Efficacy of Erlotinib in Non‑small Cell Lung Cancer: A Novel Strategy to Reverse Hypoxia‑Induced Drug Resistance  \nHaojie Jiang1,2,3 · Shunhui Cai1,2,3 · Xiaojun Zhang1,2,3 · Shijie Chen1,2,3 · Chunyan Yue1,2,3 · Wu Yin1,2,3 · Yiqiao Hu1,2,3  \nReceived: 7 May 2025 / Accepted: 3 December 2025 / Published online: 3 April 2026 © The Author(s) 2026  \nAbstract  \nBackground Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality. While EGFR tyrosine kinase inhibitors (EGFR-TKIs) have improved survival, acquired resistance mediated by tumor hypoxia and HIF-1α stabilization often leads to treatment failure. This study investigated the regulatory role of HIF-1α in NSCLC drug resistance and evaluated a combined therapeutic strategy to overcome EGFR-TKI resistance.  \nMethods HIF-1α expression and downstream targets were assessed in H1975 and A549 cell lines using RT-qPCR and Western blot. Functional assays, including cell proliferation, apoptosis, invasion, lactate production, and ROS measurements, were performed following HIF-1α siRNA transfection and/or erlotinib treatment. Bioinformatics analyses of public datasets evaluated clinical relevance and pathway enrichment.  \nResults HIF-1α knockdown inhibited glycolysis, reduced lactate production, and alleviated hypoxia-induced oxidative stress. Combined treatment with HIF-1α siRNA and erlotinib synergistically suppressed cell proliferation, induced apoptosis, and inhibited invasion more effectively than single-agent treatments. Mechanistically, EGFR signaling positively regulated HIF-1α stability via the PI3K/AKT and MEK/ERK pathways. Bioinformatics confirmed that high HIF-1α expression correlates with poor prognosis in NSCLC patients.  \nConclusion Targeting HIF-1α disrupts metabolic reprogramming and hypoxia adaptation, thereby enhancing erlotinib efficacy. This combined approach highlights the therapeutic potential of HIF-1α inhibition as a novel strategy to overcome EGFR-TKI resistance in NSCLC.  \nHaojie Jiang and Shunhui Cai contributed equally to this work.  \n* Chunyan Yue [yuechunyan@nju.edu.cn](yuechunyan@nju.edu.cn)  \n* Wu Yin [wyin@nju.edu.cn](wyin@nju.edu.cn)  \n* Yiqiao Hu [huyiqiao@nju.edu.cn](huyiqiao@nju.edu.cn)  \n1 State Key Laboratory of Pharmaceutical Biotechnology, Medical School & School of Life Sciences, Nanjing University, SLiS Building, Xianlin Campus, No. 163 of Xianlin Avenue, Qixia District, Nanjing 210093, China  \n2 Jiangsu Key Laboratory for Nano Technology, Nanjing University, Nanjing, China  \n3 Institute of Drug R&D, School of Life Science, Nanjing University, Nanjing, China  \n1 Introduction  \nNon-small cell lung cancer (NSCLC), accounting for 85% of all lung cancer cases, continues to pose a severe global health challenge [1]. According to the 2022 Global Cancer Statistics [2], lung cancer remains the leading cause of cancer incidence and mortality worldwide, with an estimated 2.5 million new cases and over 1.8 million deaths in 2022 [2] . Notably, approximately 75% of patients are diagnosed at an advanced stage (stage III–IV), resulting in a 5-year survival rate of less than 20%[3 , 4] . Although epidermal growth factor receptor (EGFR) -targeted tyrosine kinase inhibitors (EGFR-TKIs) initially achieve significant clinical benefits, the widespread emergence of drug resistance severely compromises their long-term efficacy [5] .  \nIncreasing evidence indicates that the hypoxia-inducible factor-1α (HIF-1α) signaling pathway plays an important role in the occurrence, development, and drug resistance progression of NSCLC [6–8] . Recent studies have shown that the expression level of HIF-1α in EGFR-TKI-sensitive NSCLC tissues is significantly abnormal, increasing by 15–20 times compared with normal lung tissues [9–11] . This over-activated state not only promotes the adaptation of tumor c","cbCaid22OZRdlNCV","https://ap.wps.com/l/cbCaid22OZRdlNCV","pdf",5511154,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction","[{\"question\":\"Why does hypoxia and HIF-1α matter in EGFR-TKI resistance in NSCLC?\",\"answer\":\"HIF-1α stabilization promotes adaptation to the hypoxic microenvironment and supports metabolic and signaling changes that drive resistance. This leads to impaired long-term efficacy of EGFR-TKIs.\"},{\"question\":\"How was HIF-1α investigated in the study’s experiments?\",\"answer\":\"HIF-1α expression and downstream targets were measured in H1975 and A549 cells using RT-qPCR and Western blot. Functional assays assessed proliferation, apoptosis, invasion, lactate production, and ROS after HIF-1α siRNA and/or erlotinib treatment.\"},{\"question\":\"What is the main finding from combining HIF-1α siRNA with erlotinib?\",\"answer\":\"The combination synergistically suppresses cell proliferation, induces apoptosis, and inhibits invasion more effectively than single-agent treatment. The study links this effect to disruption of metabolic reprogramming and hypoxia adaptation.\"}]","HIF-1α siRNA Enhances the Efficacy of Erlotinib in Non-small Cell Lung Cancer - A Novel Strategy to Reverse Hypoxia-Induced Drug Resistance | PDF",1790149679,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/319e10ea07d56d33ef48172b23c48d0b.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/243801b627cce6db913b4927ea3f29f0.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/622b17017ba5721adbedb00a3052770f.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6f0dd22354a20d2f0e7d753f43b9025f.webp",980,1301]